Jaagsiekte sheep retrovirus (JSRV) is the causative agent of ovine pulmonary adenocarcinoma, a transmissible lung cancer in sheep. Previous experiments in differentiated murine tissue culture cell lines suggested that the disease specificity of JSRV for secretory lung epithelial cells (type II pneumocytes an Clara cells) reflects transcriptional specificity of the viral long terminal repeat (LTR) for these cells. To test this in vivo, transgenic mice carrying the bacterial beta-galactosidase (β-Gal) gene driven by the JSRV LTR were generated. Two transgenic lines showed β-Gal expression in the lungs but not other tissues of F1 animals, although transgene silencing in subsequent generations was a major problem. The cells expressing the transgene were identified by two-and three-color immunofluorescence for marker proteins of type II pneumocytes (surfactant protein C [SPC]) and Clara cells (CC10) as well as for a T7 gene 10 epitope present in the β-Gal reporter. F1 animals from both lines showed transgene expression in type II pneumocytes, but somewhat surprisingly not in Clara cells. Expression was not detected in bronchiolo-alveolar stem cells (BASCs) either. These results indicate that the JSRV LTR is specifically active in type II pneumocytes in the mouse lung, which is consistent with the fact that JSRV-induced OPA tumors in sheep largely have phenotypic markers of type II pneumocytes.
Introduction
The disease jaagsiekte is an acute and contagious respiratory ailment in sheep and goats, predominantly found in Europe, Africa and Latin America (Palmarini et al., 1997) . Afflicted animals exude foamy white fluid from their nose, ultimately succumbing to pulmonary failure. Jaagsiekte, now termed ovine pulmonary adenocarcinoma (OPA), is manifested by multifocal tumors of secretory epithelial cells (type II pneumocytes and/or Clara cells); excess secretory products from the tumor cells comprise the nasal fluids typical of the disease. Type II pneumocytes are located in the alveoli, where they secrete surfactant necessary for maintaining hydration and gas permeability of the alveoli. Clara cells are located in the bronchioles, where they secrete products involved in the metabolism of foreign agents (Widdicombe and Pack, 1982) . The causative agent of OPA is an exogenous betaretrovirus, jaagsiekte sheep retrovirus (JSRV) (Palmarini et al., 1999a; Holland et al., 1999) . JSRV is unique in that its envelope protein functions as an oncogene that can transform cells in culture (Maeda et al., 2001; Pannell et al., 2000; Allen et al., 2002) and in vivo (Wootton et al., 2005; Caporale et al., 2006; Dakessian et al., 2007) .
Another unusual feature of JSRV infection is that the virus displays unusually strong tissue specificity in vivo for expression in lung epithelial cells. In contrast to many other oncogenic retroviruses (e.g. murine leukemia viruses (Fan, 1997) where productive infection is systemic, even end-stage sheep with OPA largely show expression of viral proteins only in the tumor cells (Palmarini et al., 1996) . On the other hand, evidence for viral infection in hematopoietic cells (by nested PCR) can be found even at relatively early times after infection (Holland et al., 1999) ; however these cells apparently do not express the virus. Two possible mechanisms could affect the in vivo tissue specificity of JSRV. First, the tissue distribution of Available online at www.sciencedirect.com Virology 372 (2008) 398 -408 www.elsevier.com/locate/yviro the JSRV receptor could influence cell type specificity, if the receptor is specifically expressed in lung epithelial cellssimilar to the restriction of HIV-1 infection to CD4-(and CCR5-or CXCR4-) bearing cells in humans (Moore, 1997) . However, the JSRV receptor (hyaluronidase 2 [hyal2]) has been identified (Rai et al., 2001) , and it is distributed broadly among different cell types. This is consistent with the facts that JSRV viral DNA can be found in vivo in non-lung epithelial cells (Palmarini et al., 1996) , and that all ovine cell lines tested could support JSRV replication in vitro at some level (Palmarini et al., 1999b) . Thus, in vivo lung specificity for JSRV infection cannot be explained by the distribution of the receptor. This supports the second mechanism, transcriptional specificity of the JSRV long terminal repeat (LTR). Retroviral LTRs carry the viral transcriptional signals in their U3 regions, including the basal promoter (e.g. TATA element) as well as upstream enhancer elements that bind cellular transcription factors (Fan, 1997) . For some retroviruses, the LTR enhancers show cell type specificity -e.g. the preferential activity of the Moloney murine leukemia virus (M-MuLV) LTR in T-lymphoid cells. This specificity is associated with the ability of M-MuLV to induce T-lymphomas, resulting from preferential insertional activation of cellular proto-oncogenes in T-lymphoid cells (Chatis et al., 1984; Li et al., 1987; Lenz et al., 1984) . For most retroviruses, the transcriptional specificities of the LTRs are not absolute. Even though the M-MuLV LTR has transcriptional preference for T-lymphoid cells, it clearly functions in other cell types since in vivo productive infection is observed in non-T-lymphoid cells, including other hematopoietic cells and non-hematopoietic cells (Davis et al., 1987) . In contrast, the JSRV LTR would have to show very strong lung cell specificity if this were the explanation for the in vivo tissue specificity of JSRV, since expression of viral proteins is largely only observed in tumor cells in the lung.
We previously studied the transcriptional specificity of the JSRV LTR in transient transfection assays (Palmarini et al., 2000; McGee-Estrada et al., 2002 . A reporter plasmid consisting of the JSRV LTR driving the firefly luciferase gene was tested in a variety of murine cell lines derived from different cell types. With the exception of two lung epithelial-derived cell lines (MLE-15 and mtCC1-2), the other cell lines showed little activity of the JSRV LTR-luc reporter. MLE-15, which showed the highest reporter activity, was derived from a tumor of type II pneumocytes arising in a mouse containing a transgene consisting of SV40 Large T Antigen driven by the surfactant protein C (SPC) promoter (Wikenheiser et al., 1993) . mtCC1-2 showed significant but lower JSRV LTR activity, and was similarly derived from a Clara cell tumor from a mouse containing an SV40 Large T Antigen -Clara cell protein 10 (CC10) promoter transgene (Magdaleno et al., 1997) . These results were consistent with the fact that most OPA tumors consist predominantly of cells with properties of type II pneumocytes, but they often also contain cells with Clara cell properties (Platt et al., 2002) . They also support the hypothesis that the in vivo tissue specificity of JSRV is determined transcriptionally by the LTR. Indeed, the JSRV LTR contains transcription factor binding motifs known to be important for type II pneumocytespecific genes, including HNF-3β and C/EBPα (McGee-Estrada et al., 2002) . Deletion or mutation of these sites strongly reduced activity of the JSRV LTR in MLE-15 cells (McGee-Estrada and Fan, 2006) .
In these experiments, we further investigated the tissue specificity of the JSRV LTR by generating transgenic mice carrying an LTR driving an epitope-tagged bacterial β-galactosidase gene. This allowed us to investigate the activity of the LTR in normal lung cells, and test if the specificity was that predicted by the transient transfection assays in cell lines. Experiments with other retroviral LTRs indicate that transgenic mice may provide more biologically relevant read-outs compared to transient transfection assays. Ross, Dudley and co-workers found that transgenic mice carrying mutant murine mammary tumor virus (MMTV) LTRs showed effects on hormone responsiveness, while the same constructs in transient transfection assays did not (Bramblett et al., 1995; Ross et al., 1990) .
Studies of JSRV LTR expression in transgenic mice would not only allow identification of target cells for infection, but they might provide insights into target cells for oncogenic transformation. In particular, JSRV could be transforming differentiated type II pneumocytes and/or Clara cells, or it could actually be transforming stem cells. The fact that many OPA tumors are of mixed phenotype (predominantly type II-derived cells, but with varying proportions of Clara-derived cells (Platt et al., 2002) would be consistent with tumorigenesis of a stem cell. Recently, a stem cell population has been identified in the lung that can differentiate into both type II pneumocytes and Clara cells (Kim et al., 2005) . These cells, bronchioloalveolar stem cells (BASCs), are found in the transitional zone between the bronchioles and the alveoli -the bronchiolo-alveolar ductal 
Results

Generation of LTR-lacZ transgenic mice
To study the cell type specificity of the JSRV LTR, a reporter construct (pJS21-lacZ) was generated in which the bacterial beta-galactosidase (lacZ) gene was cloned downstream of the entire 5′ JSRV LTR (Fig. 1A) . The version of the lacZ gene used also contained an inserted epitope from the bacteriophage T7 gene 10 protein that would allow for detection with a monoclonal antibody (Lindner et al., 1997) . The fidelity of the JSRV LTR and coding regions of pJS21-lacZ were confirmed by DNA sequencing. To test if the LTR reporter construct is specifically active in lung epithelial cell lines, the plasmid was transfected into the murine type II pneumocyte-derived MLE-15 cell line (Wikenheiser et al., 1993) , and beta-galactosidase activity was measured. For comparison, a lacZ reporter plasmid driven by the highly active human cytomegalovirus (CMV) immediate early promoter was also tested, as well as a CMV promoter-containing plasmid that did not encode lacZ (pcDNA3.1). As shown in Fig. 1B , pJS21-lacZ showed significant activity in MLE-15 cells (ca. 25% the level of pCMVlacZ). In contrast, parallel transfections in murine NIH-3T3 fibroblasts showed very low activity of pJS21-lacZ compared to pCMV-lacZ, indicating that the LTR is essentially inactive in this cell line. This was consistent with our previous studies of JSRV LTR specificity (Palmarini et al., 2000) . These results indicated that the JSRV-lacZ reporter construct was active in 
The transgenic lines obtained are shown, and the sexes of the founders are indicated. All founders were positive for transgene DNA as measured by PCR, and results for transgenic F1, F2 and F3 animals are shown. Expression was determined by sacrificing animals and performing X-gal stains on frozen sections from lung, spleen, liver and kidney. Only the lungs showed expression. +, expression in one or more transgenic animals (for F1-F3 generations; backcrossing to C57Bl6 mice). −, no transgene expression observed in at least four F1 mice tested. If F1 litters were negative by this criterion, they were not bred to subsequent generations. n/a, not applicable. MLE-15 cells, and it showed the expected cell-type specificity when assayed by transient expression in a cell line. The LTR-lacZ gene was excised from pJS21-lacZ by digestion with the appropriate restriction endonucleases, purified and provided to the UCI Genetically Modified Rodent Facility. The purified LTR-lacZ gene was microinjected into fertilized mouse ova, which were then implanted into pseudopregnant foster mothers. PCR screening of DNAs from tail snips identified 11 pups (9 males and 2 females) that contained the transgene (A-K, Table 1 ). These transgenic founders were crossed with non-transgenic C57Bl6 animals, and all eleven founders transmitted the transgene to F1 animals.
Expression of the transgene in different tissues
To test for transgene expression, transgenic F1 animals were sacrificed and lung, spleen, liver and kidney tissues were frozen in OTC medium, and frozen sections were prepared for assays of transgene expression. The lung was of primary interest, in light of the previous in vitro studies of JSRV LTR specificity in lung epithelial cell lines, and also the fact that JSRV induces lung cancer in sheep. The spleen was chosen because it supports replication of many retroviruses such as murine leukemia virus (Coffin et al., 1997) . The liver and kidney do not support replication of a number of retroviruses (e.g. murine leukemia viruses); in the case of the liver, hepatocytes do not express receptors for MuLV (MacLeod and Kakuda, 1996) , while kidney cells do not have division capacity (a prerequisite for infection by simple retroviruses). On the other hand, transcription factors such as HNF3 and C/EBP drive expression of both liver-specific and lung-specific genes, and expression of the JSRV LTR in MLE-15 cells has been found to be strongly influenced by the presence of binding sites for these factors. An in situ X-gal assay was performed on sections from each tissue (Alam and Cook, 1990; Ausubel, 1997) ; lacZ-positive cells appeared dark blue under light microscopy.
Of the 11 transgenic founders, two (A and G) yielded transgenic F1 progeny that expressed the transgene (Table 1) . Three A line transgenic F1 animals showed transgene expression in the lung, but not in liver, spleen and kidney (Fig. 2 ). This would be consistent with the JSRV LTR driving transgene expression in a lung-specific manner. In the first A line F1 litter, two transgenic animals did not show transgene expression (in addition to the three that did). This could represent segregation of non-expressing transgenes from expressing transgenes, or alternatively silencing of the transgene in some animals. In any event, two A line expressing transgenic F1 animals were bred, and F2 transgenic animals were tested. None of them showed transgene expression in lung or other tissues. In addition, the A line founder was re-bred, yielding more F1 transgenic animals. Some of these F1s did show transgene expression in the lung, but the levels of expression were reduced. Typically less than five isolated blue stained cells were visible in an entire lung section, in contrast to the clusters (up to 12) of intensely blue cells visible in the F1s from the initial litter (Fig. 2) . These results would be more consistent with transgene silencing. After the F1 and F2 animals were analyzed, the A line founder was sacrificed and analyzed. As expected, the founder showed low level transgene expression in the lung (Table 1) , but not in other tissues.
F1 transgenic animals from the G line founder showed stronger expression than for the A line. All 8 transgenic F1 animals from the first litter showed strong transgene expression only in the lung (Fig. 3) . The G line founder was repeatedly bred to yield ten more litters of F1 animals. The subsequent F1 litters showed less transgene expression as compared to the first litter (Fig. 4 ) -in some cases the level expression was similar to that observed in F1 animals from the A line, and in some cases there was no expression in the transgenic animals. Two F1 transgenic animals from the 2nd litter were bred, and the F2 animals were analyzed (Fig. 4) . In one case, the F2 transgenic animals showed low level expression, while in the other case no F2 transgenics showed expression. These results also strongly support the hypothesis that transgene silencing was occurring. Ultimately the G line founder was sacrificed and analyzed. As expected, this animal showed expression in the lung, although the level of expression was in fact low (Fig. 4) . This could have resulted from tissue mosaicism, or somatic silencing of the transgene in the lung.
Previous studies have identified DNA methylation and chromatin condensation (e.g. histone deacetylation) as causes of retrovirally transduced genes (Chen and Townes, 2000) . Furthermore, retroviral transgenic sequences have a history of being selectively silenced by host systems, perhaps as a defense mechanism against infection or tumorigenesis (Swindle and Klug, 2002) . Moreover, treatment of murine cells with the DNA demethylating against 5-Aza-cytidine activated endogenous MuLVs (Hoffmann et al., 1982) . To test the hypothesis that methylation-based silencing might be occurring in these JSRV LTR-lacZ transgenics, one litter of G line F2 pups was intraperitoneally inoculated with 5-AzaC (40 μg per animal) twice a week for 5 weeks. Under these conditions, 5-AzaC has been shown to eliminate genomic methylation and stimulate transcription of silenced genes (Jaenisch et al., 1985) . However 5-AzaC treatment of the JSRV-lacZ F2 transgenics did not result in transgene expression in the lung or other tissues at the end of the treatment period (not shown).
All other transgenic founders that did not produce transgeneexpressing F1s were sacrificed after two negative litters were obtained. They were then analyzed for transgene expression. One additional founder (I) was found to express the transgene at low levels in the lung but not in other tissues (Table 1) . This founder might not have contained the expressing transgene in its germline, or alternatively its transgene might have been subject to extremely strong silencing.
Identification of lung epithelial cells expressing the transgene
When we initiated these experiments, we anticipated obtaining transgenic lines that stably and consistently expressed the LTR-lacZ transgene. This would have facilitated identification of the lung cells expressing the transgene, the ultimate goal of these experiments. Lung tissues could be fixed and sectioned under optimal conditions. However, as shown above, apparent transgene silencing was a major issue; the G line has been maintained (currently at the F2 and F3 generations), although the animals do not currently express the transgene. Nevertheless, sufficient tissue was retained from animals from early F1 litters for more detailed analyses. We studied lung tissues from animals found to express the transgene by the initial X-gal staining. These tissues had been frozen, since β-galactosidase assays cannot be performed efficiently on fixed tissues. On the other hand, identification of cell types within the lung requires higher resolution analyses of fixed tissues sections. Therefore, frozen lung tissues from A and G line F1s were thawed and then fixed in formalin, embedded in paraffin and sectioned. Depending on the particular tissue sample, the degree to which the lung architecture was preserved varied. For some samples, welldefined alveoli were evident, while in other samples, the alveolar structure was collapsed. Nevertheless there was sufficient preservation to allow identification of the relevant cells and cell types within the lung sections.
Since JSRV-induced tumors in sheep have phenotypic markers of type II pneumocytes and/or Clara cells, we tested if these cell types were expressing the transgene in animals from the A and G lines. This was accomplished by three-color immunofluorescence, using polyclonal antisera for pre-surfactant protein C (SPC, specific for type II pneumocytes), CC10 (specific for Clara cells), and a MAb specific for the T7 protein 10 epitope (present in the transgene) (Rooney et al., 1994) . Visualization of SPC employed a secondary antibody conjugated to the Alexafluor 555 fluorophor, anti-CC10 was visualized by a secondary antibody conjugated to Alexafluor 488, and the T7 epitope was visualized by a secondary antibody conjugated to Alexafluor 647. Use of these fluorophors was important because their emission spectra were well separated. They were also advantageous because immunofluorescence at these wavelengths did not show the high autofluorescence that made use of other fluorophors (e.g. fluorescein) problematic. Staining for SPC identified individual cells in the alveolar areas of the lung (Fig. 5, panels B and F) , as expected for the distribution of type II pneumocytes. Staining for CC10 identified grouped cells lining vessels (Fig. 5 , panels D and H), as expected for Clara cells lining the bronchioles. Kim et al. (Kim et al., 2005) have recently identified bronchiolo-alveolar stem cells (BASCs) that have the capacity to divide and differentiate into both type II pneumocytes and Clara cells. They express both SPC and CC10, and are located at bronchiolo-alveolar ductal junctions. Small numbers of cells positive for both SPC and CC10 (and located near bronchioloalveolar ductal junctions) were also detected (Fig. 5, panel K) . Fig. 5 shows three-color immunofluorescent staining of lung sections from two G line F1 transgenics for the transgene (T7 epitope), SPC and CC10. In addition, the sections were stained with the DNA-binding dye DAPI, which allowed visualization of all of the cells in the section. As shown in panels B and F, To quantify the transgene expression in the different lung cell types, multiple lung sections from the A and G line F1 animals were analyzed by 3-color immunofluorescent staining, all of the fluorescent cells in the sections were tabulated, and the results are shown in Table 2 . For the one A line animal, 5.5% of type II pneumocytes (SPC+) were found to express the transgene, while no Clara cells (CC10+) did. One BASC cell (SPC+CC10+) was detected, and it was negative for transgene expression. Only 14 / 137 (10%) of the transgene expressing cells were negative for SPC expression, indicating that type II pneumocytes accounted for the great majority of transgene-expressing cells. Similar results were obtained for two G line F1 animals. As expected, the overall level of transgene expression was higher, with 14.8% of the type II pneumocytes showing expression. Similar to the A line, no transgene expression was detected in Clara cells or the rare BASC cells. Taken together, these results indicated that the JSRV LTR was active in type II pneumocytes in these transgenic lines, while expression in Clara cells was not detected.
While the lack of expression of the transgene in Clara cells was statistically significantly different from the level of expression in type II pneumocytes for both the A and G line animals (P b 1.9 × 10 − 7 by the Fisher Exact test), the small number of BASC cells detected in the sections described in Table  2 did not allow conclusions to be drawn. Therefore additional sections from G line F1 transgenic lungs were analyzed. To facilitate the analysis, sections were scanned only for BASC cells (doubly positive for SPC and CC10, located at bronchioloalveloar duct junctions) and the BASC cells were scored for expression of the transgene. In total, 23 BASC cells were identified, and none were found to express the transgene. This level was statistically significantly different from the 15% level of expression in type II pneumocytes (P b 0.04 by the Fisher Exact test).
Discussion
In this report we studied the in vivo tissue and cell-type specificity of the JSRV LTR in a transgenic mouse model. The mice contained a transgene consisting of the JSRV LTR driving β-galactosidase, which allowed detection of transgene expression by X-gal staining of frozen sections. The presence of a T7 gene 10 epitope in the transgene also allowed detection of expression by immunofluorescent staining with a specific MAb. In both the A and G line transgenic F1 animals, transgene expression was detected in lung cells, with G line animals showing higher levels of expression than A line animals. Thus the results were very likely to reflect JSRV LTR specificity and not effects of chromosomal insertion sites on the specificity of the transgene expression.
Transgene expression was not observed in spleen, liver or kidney, indicating that the JSRV LTR drove transgene expression in a lung-specific manner. It would have been desirable to further assess the tissue specificity of the transgene by surveying a wider variety of somatic tissues. However, as discussed below, the strong transgene silencing in these lines prevented this. By the time the extent of silencing was appreciated, F1 litters from the original A and G founders no longer expressed the transgene, even in the lung. The only tissues available for analysis were archival samples from the very first or second F1 litters, and in those cases a limited selection of tissues were harvested to facilitate the initial screening.
Three color immunofluorescent staining with markers for type II pneumocytes (SPC), Clara Cells (CC10) and the transgene (the T7 epitope) allowed identification of the transgeneexpressing cells. In both the A and G lines, type II pneumocytes accounted for the vast majority of transgene expressing cells. This indicated that the JSRV LTR is active in type II pneumocytes in vivo. In a recent systematic study, the great majority (16/17) of JSRV-induced OPA tumors in sheep consisted predominantly of Type II pneumocytes (Platt et al., 2002) . This supports the notion that the tumor specificity of JSRV for type II pneumocytes is strongly influenced by the transcriptional specificity of the JSRV LTR for these cells. These results were also consistent with our previous finding that the type II pneumocyte-derived murine cell line MLE-15 supports the highest level of JSRV LTR activity in transient transfection assays.
The results also indicated that the transgene was not detectably expressed in Clara cells, as measured by lack of costaining with the Clara cell marker CC10 and absence of transgene expression in the bronchioles. This would suggest that mature Clara cells are not targets for JSRV infection and transformation. This was somewhat surprising since ovine OPA tumors often show evidence for presence of Clara cells, although in the recent study of Platt et al. (Platt et al., 2002) , the percentages of cells with morphological characteristics of Clara cells were typically low (b 10%). Only 1/17 tumors consisted of cells with predominantly Clara cell properties. We previously found that the JSRV LTR is active in the murine Clara cellderived cell line mtCC1-2, although its level of expression was less than for the type II pneumocyte-derived MLE-15 cells (Palmarini et al., 2000) .
Another attractive explanation for the origin of OPA tumors with mixed type II pneumocyte and Clara cell characteristics could be that the targets for JSRV infection and transformation are the BASC cell progenitors that can differentiate into either Type II pneumocytes or Clara cells. However, extended analysis of the G line transgenics did not identify any transgeneexpressing BASC cells, and the results were statistically significant. Thus these results do not support the hypothesis that the true targets for JSRV infection and transformation are BASC cells. An alternative explanation could be that during oncogenic transformation of type II pneumocytes, a minority of the cells undergo transition to a phenotype resembling Clara cells, including expression of CC10.
In a recent publication, Hendrickson et al. studied in vivo infection of mice with lentiviral vectors driven by JSRV LTR, SPC or CC10 promoter/enhancer sequences (Hendrickson et al., 2007) . They found transgene expression was observed in Type II pneumocytes from the SPC driven lentiviral vector, and in Clara cells from the CC10 promoted lentiviral vector. However, expression was not detected in non-respiratory tissues following delivery of the lentiviral vectors containing the JSRV sequences to mice. These results were consistent with the ability of the JSRV LTR to drive expression in lung epithelial cells, although the JSRV chimeric LTR did not drive vector expression as specifically as chimeric LTRs driven by enhancers from the SPC or CC10 promoters. The somewhat broader tissue specificity of the chimeric JSRV LTR might have reflected interaction of JSRV enhancer elements with other transcription motifs in the chimeric LTR of the vector, or omission of some specificity elements from the JSRV LTR. It is also interesting that Platt et al. (Platt et al., 2002) observed JSRV protein expression in lung macrophages from sheep with OPA. This might have reflected JSRV expression in macrophages, or alternatively phagocytosis of epithelial tumor cells. Apparent transgene silencing was a significant technical challenge in these experiments. This was evident as lack of (or diminished) transgene expression in succeeding F1 litters from both the A and G line founders, which was extensively documented for the G line in Fig. 4 . Indeed, transgene silencing may have also been responsible for the fact that only 3/11 transgenic founders expressed the transgene, with 2/11 showing expression in some F1 animals. Operationally, this has limited further analysis of these transgenic lines. Stably expressing the JSRV LTR-lacZ transgenic lines would have facilitated further exploration of transgene expression in other tissues (e.g. macrophages and other hematopoietic cells). Isolation and culture of BASC cells from such lines would also have allowed study of transgene expression in cells as they differentiate into mature type II pneumocytes or Clara cells. However, these experiments could only analyze the archival tissues harvested during the initial screenings. In the future, it would be possible to address some of these questions, by generating new transgenic founders and extensively analyzing early F1 offspring, even before their transgene expression (which requires sacrificing the animals) is determined.
Silencing of transgenes in transgenic mice has been observed in many situations. In particular, retroviral sequences have been found to be subjected to silencing in a variety of contexts. For instance, germline infection of Moloney murine leukemia virus yielded some proviruses that expressed, but many did not . More recently, silencing of retroviral vector transgenes by chromatin remodeling and formation of repressive histone structures has been reported (Pannell et al., 2000) . Similarly, the majority of (but not all) endogenous retroviral proviruses in many species also are not expressed, even though they are present in high copy numbers. It has been proposed that this silencing may reflect a host response for limiting expression of endogenous retroviruses . Indeed, germline infection of MuLV-based retroviral vectors results in frequent silencing, similar to endogenous MuLV-related proviruses. On the other hand, substitution of lentiviral LTRs onto the vectors resulted in high level expression from the germline, indicating that MuLV (but not lentiviral) LTR sequences are targets for gene silencing (Lois et al., 2002) . Thus it is plausible that JSRV LTR sequences could also be subject to specific silencing in these transgenic mice. We also observed low frequencies of expression of a transgene expressing the JSRV env gene under control of the cellular surfactant A (SPA) promoter (Dakessian et al., 2007) . (Both SPA and SPC are specifically expressed in type II pneumocytes, with SPA transcription occurring later in embryogenesis). Thus it is possible that efficiently silencing of JSRV coding sequences also occurs in transgenic mice.
Several mechanisms have been reported in transcriptional silencing of cellular genes, including DNA methylation, histone deacetylation, and chromatin condensation (Wolffe and Matzke, 1999; Attwood et al., 2002; Dillon, 2004) . For retroviruses, in vitro infection of cells with retroviruses or retroviral vectors shows evidence of gene silencing, and in some cases this is mediated (at least initially) by DNA methylation. For example, when methylated Moloney murine leukemia virus-based proviruses were introduced into human embryonic stem cells, proviral association with proteins containing methyl-CpG binding domains (including histone deacetylases) was observed (Lorincz et al., 2001 ). However, incubation of infected cells in 5-AzaC results in activation of inactivated proviruses in some but not all situations (Conklin et al., 1982; Hoeben et al., 1991) . However, treatment of G line F2 mice with 5-AzaC did not increase transgene expression, indicating that silencing of the JSRV LTR-lacZ transgene was not exclusively dependent on methylation. Gaudet et al. (Gaudet et al., 2003) also studied mice genetically lacking the major DNA methyl transferase. In these mice, genetically transmitted M-MuLV proviruses were not activated.
The transgene silencing observed in this experiments apparently involves different or additional mechanisms than DNA methylation. In the future, it would be interesting to test if treatment with a histone de-acetylase inhibitor such as trichostatin A (alone or in combination with 5-AzaC) can activate the transgene from the JSRV LTR-lacZ transgenic mice or cells derived from them, as reported for other retroviruses (Katz et al., 2007) . Treatment of mouse cells (and mice) with the halogenated pyrimidines BrdU and IdU has been shown to induce expression of endogenous MuLV proviruses (Lowy et al., 1971; Aaronson, 1971; Besmer et al., 1975; McCubrey et al., 1982) . It is unclear if these nucleosides are affecting DNA methylation, since methylation is predominantly at C residues; some other mechanism might be affected. Thus it could be interesting to test the effects of halogenated pyrimidines on expression of the JSRV LTR-lacZ transgene.
Materials and methods
Transgene plasmid
pJS21-lacZ was constructed by substituting sequences from pcDNA3.1/HisB/lacZ plasmid (Invitrogen) into the psJS21-luc plasmid constructed previously (Palmarini et al., 2000) . The luciferase gene was replaced by the lacZ ORF from pcDNA3.1/ HisB/lacZ using established procedures (Ausubel, 1997) . pCMV-lacZ was constructed by removing the JSRV LTR sequences in pJS21-lacZ and substituting the CMV immediately early promoter upstream of the lacZ ORF.
Pronuclear injections
DNA injections into fertilized Balb/c X C57/Bl6J (CB6F1) mouse ova followed by implantation into pseudopregnant foster mothers were performed by the Genetically Modified Rodent Facility at the University of California, Irvine. C57Bl/6J mice were purchased from Jackson Laboratories, Inc., Bar Harbor, ME. DNA restriction fragments for microinjection were separated from plasmid sequences by electrophoresis on type II agarose gels (Fisher Scientific, Houston, TX). Bands containing the desired fragments were excised and the DNA was recovered with QIAquick Gel Extraction Kit (Qiagen Inc, Valencia CA) and purified using the GeneClean Spin Kit (QBiogene, Irvine, CA).
Genotyping
Genomic DNAs from mice were isolated from tail clippings by incubation in proteinase K (20 mg/ml in TE Buffer, pH 8.0 at 37°C), followed by phenol-chloroform extraction (Lin et al., 1989) . PCR detection of the transgene was performed using the HotMaster PCR Kit (Eppendorf, Hamburg, Germany) with primer sets recognizing sequences from the JSRV Long Terminal Repeat (Genbank Accession no. AF105220): 5′-TGGGAGCTCTTTGG-CAAAAGCC-3′, 5′-CAGCGGATTTTTACACAATCACCGG-3′. All primers were synthesized by Invitrogen, Carlsbad, CA.
Tissue preparations
Animals were killed and subjected to full necropsy. Tissues were embedded in Tissue-Tek® O.C.T. compound (Fisher) and stored at − 20°C. Samples for immunofluorescence microscopy were thawed, fixed in 20% neutral buffered formalin (SigmaAldrich, St. Louis, MO) and embedded in Paraplast X-tra tissue embedding medium (Fisher). Sections at 8 μm thickness were cut on a microtome and mounted on Superfrost Plus microscope slides (Fisher).
Cell lines
MLE-15 cells (provided by J. Whitsett, Cincinnati, OH) were grown in RPMI 1640 (Gibco BRL), 2% FBS, 0.5% ITS (Sigma), modified with the addition of 5 mg/L transferrin, 10 mM HEPES, 1 3 1028 M b-estradiol and 1 3 1028 M hydrocortisone. 3T3 (ATCC) were grown in DMEM (ATCC) and 10% FBS. Both cell types were cultured at 37°C with 5% CO2.
Reporter assays
For transient transfections, 2 × 10 5 cells were plated per well on six-well plates (Falcon) approximately 24 h before transfection. For each well, 300 ng of plasmid DNA (200 ng of pcDNA3.1, pJS21-lacZ, or pCMV-lacZ) and 6 ml fugene (Boehringer) were used as recommended by the manufacturers. After 48 h, transfected cells were washed with PBS and lysed with 500 ml/well of passive lysis buffer (Promega). Luminescent β-Gal assays were performed on 25 μl of cleared lysate with the Beta-Glo Assay System (Promega) and light output was integrated over 10 s at room temperature using a Moonlight 2010 luminometer (Analytical Luminescence Laboratory).
X-gal staining
Frozen tissue were sectioned at 15 μm, mounted on Superfrost Plus microscope slides (Fisher), and fixed in 8% glutaraldehyde. Sections were then stained in 5-bromo-4-chloro-3-indolyl-beta-D-galactopyranoside (X-gal) staining solution to evaluate transgene expression as described previously (John Wiley & Sons., 1990) .
Immunofluorescence
Tissue sections on slides were deparaffinized in 100% xylene and rehydrated in ethanol gradients (2 × 100%, 2 × 95%) (Ausubel, 1997) . For immunohistochemistry, samples were first subjected to antigen retrieval by submersion in 0.1 M sodium citrate buffer (pH 6.0) and microwaving for 20 min. Sections were then incubated with rabbit polyclonal anti-SPC (HA) antibody (1:200, Chemicon International), goat polyclonal anti-CC10 antibody (1:1000, Chemicon International), and mouse monoclonal Anti-Xpress (Invitrogen) in 5% donkey serum overnight at 4°C. After washing, the samples were incubated overnight at 4°C in 5% donkey serum with the following antibodies: donkey anti-goat IgG conjugated to Alexa-Fluor 488 (1:200), donkey anti-rabbit IgG conjugated to Alexa-Flour 555 (1:200), and donkey anti-mouse IgG conjugated to . Tissues were visualized with fluorescent microscopy at 200× magnification on a Zeiss LSM510-META NLO (multi-photon) confocal microscope.
